Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 1, 2011, Pages 1-10

  Prasad, Shashi ^a   Cody, Virginia ^a   Saucier Sawyer, Jennifer K ^b   Saltzman, W Mark ^b   Sasaki, Clarence T ^c   Edelson, Richard L ^a   Birchall, Martin A ^d   Hanlon, Douglas J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University   (United States)

^c YALE UNIVERSITY   (United States)

^d ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

Author keywords

Antigen delivery; Dendritic cell; Immunotherapy; Nanoparticles; Polymers

Indexed keywords

ANTI-TUMORS; ANTIGEN DELIVERY; ANTIGEN PRESENTATION; BLOOD MONOCYTES; CANCER CELLS; CELL LINES; DENDRITIC CELLS; ELIMINATION METHOD; ENCAPSULATION EFFICIENCY; HEAD AND NECK; HEAD-AND-NECK CANCER; IMMUNE MECHANISM; IMMUNOTHERAPY; LYSATES; POLY(LACTIC-CO-GLYCOLIC ACID); POLYMER NANOPARTICLES; RELEASE KINETICS; SQUAMOUS CARCINOMA; T CELLS; T-CELL RESPONSE; TUMOR CELLS;

ANTIGENS; CELL CULTURE; DENDRIMERS; ENCAPSULATION; NANOPARTICLES; POLYMERS; TUMORS;

CELLS;

DENDRITIC CELL VACCINE; DRUG VEHICLE; GAMMA INTERFERON; INTERLEUKIN 10; NANOPARTICLE; POLYGLACTIN; POLYMER; PROTEIN HYDROLYSATE; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN PRESENTATION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL LYSATE; CELL THERAPY; CONTROLLED STUDY; COST CONTROL; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SYNTHESIS; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; NANOENCAPSULATION; SOLID TUMOR;

CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NEOPLASMS; POLYMERS;

EID: 78751681345     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2010.07.002     Document Type: Article

References (36)

1. Figdor C.G., de Vries J.M., Lesterhuis W.J., Melief C.J.M. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10:475-480.
2. Zhang Y., Ma B., Zhou Y., Zhang M., Qiu X., Sui Y., et al. Dendritic cell fused with allogeneic breast cancer cell line induces tumour antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat 2007, 105:277-286.
3. Jenne L., Schuler G., Steinkasserer A. Viral vectors for dendritic cell based immunotherapy. Trends Immunol 2001, 22:102-107.
4. Jager E., Ringhoffer M., Karbach J., Arand M., Oesch F., Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic- T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996, 66:470-476.
5. Riker A., Cormier J., Panelli M., Kammula U., Wang E., Abati A., et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 1999, 126:112-120.
6. Solbrig C.M., Saucier-Sawyer J.K., Cody V., Saltzman W.M., Hanlon D.J. Polymer nanoparticles for immunotherapy from encapsulated tumor associated antigens and whole tumor cells. Mol Pharm 2007, 4:47-57.
7. Scholl I., Boltz-Nitulescu G., Jensen-Jarolim E. Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Control Release 2005, 104:1-27.
8. Kovacsovics-Bankowski M., Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC Class I molecules. Science 1995, 267:243-246.
9. Shen Z., Reznikoff G., Dranoff G., Rock K.L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997, 28:2723-2730.
10. Waeckerle-Men Y., Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 2005, 57:475-482.
11. Gupta R.K., Rost B.E., Relyvelt E., Siber G.R. Adjuvant properties of aluminium and calcium compounds. Vaccine design: the subunit and adjuvant approach 1995, 229-248. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
12. Nakoaka R., Tabata Y., Ikada Y. Adjuvant effect of biodegradable poly (d,l-lactic acid) granules capable for antigen release following intraperitoneal injection. Vaccine 1996, 14:1671-1676.
13. Peppas L.B., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004, 56:1649-1659.
14. Diwan M., Elamanchili P., Lane H., Gainer A., Samuel J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target 2003, 11:495-507.
15. Kwon Y.J., Standley S.M., Goh S.L., Frechet J.M.J. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J Control Release 2005, 105:199-212.
16. Levine M.M., Sztein M.B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 2004, 5:460-464.
17. Partidos C.D., Vohra P., Jones D., Farrar G., Steward M.W. CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles. J Immunol Methods 1997, 206:143-151.
18. Elamanchili P., Lutsiak C.M.E., Hamdy S., Diwan M., Samuel J. ″ Pathogen-mimicking″ nanoparticles for vaccine delivery to dendritic cells. J Immunother. 2007, 30:378-395.
19. Murillo M., Grillo M.J., Rene J., Marin C.M., Barberan M., Blasco J.M., et al. A Brucella ovis antigenic complex bearing (poly-Σ-caprolactone) microparticles confer protection against experimental brucellosis in mice. Vaccine 2001, 19:4099-4106.
20. Ren J.M., Zou Q.M., Wang F.K., He Q., Chen W., Zen W.K. PELA microspheres loaded H. pylori lysates and their mucosal immune response. World J Gastroenterol 2002, 8:1098-1102.
21. Balz V.S.K., Gotte K., Bockmuhl U., Petersen I., Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papilloma virus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003, 63:1188-1191.
22. Carrasquillo K.G., Stanley A., Aponte-Carro J.C., De Jesus P., Costantino H.R., Bosques C.J., et al. Non-aqueous encapsulation of excipient-stabilized spray-freeze dried BSA into poly(lactide-coglycolide) microspheres results in release of native protein. J Control Release 2001, 76:199-208.
23. Ravi Kumar M.N.V., Bakowsky U., Lehr C.M. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004, 25:1771-1777.
24. Bala I., Hariharan S., Ravi Kumar M.N.V. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004, 21:387-422.
25. Johansen P., Gomez J.M.M., Gander B. Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Exp Rev Vaccines 2007, 6:471-474.
26. Nestle F.O., Farkas A., Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 2005, 17:163-169.
27. Johansen P., Gander B., Merkle H.P., Sesardic D. Ambiguities in the preclinical quality assessment of microparticulate vaccines. Trends Biotechnol 2000, 18:203-211.
28. Sesardic D., Dobbelaer R. European Union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine 2004, 22:2452-2456.
29. Sandor M., Enscore D., Weston P., Mathiowitz E. Effect of protein molecular weight on release from micron-sized PLGA microspheres. J Control Release 2001, 76:297-311.
30. Sun S.W., Jeong Y.I., Jung S.W., Kim S.H. Characterization of FITC-albumin encapsulated poly (d,l-lactide-co-glycolide) microspheres and its release characteristics. J Microencapsul 2003, 20:479-488.
31. O'Hagan D.T., Jeffery H., Davis S.S. The preparation of poly (lactide-co-glycolide) microparticles. III. Microparticle/polymer degradation rates and the in vitro release of a model protein. Int J Pharm 1994, 103:37-45.
32. Hans M.L., Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002, 6:319-327.
33. Audran R., Peter K., Dannull J., Men Y., Scandella E., Groettrup M., et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003, 21:1250-1255.
34. Carrasquillo K.G., Carro J.C.A., Alejandro A., Toro D.D., Griebenow K. Reduction of structural perturbations in bovine serum albumin by non-aqueous microencapsulation. J Pharm Pharmacol 2001, 53:115-120.
35. Chen D.S., Soen Y., Stuge T.B., Lee P.P., Weber J.S., Brown P.O., et al. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med 2005, e265:2.
36. Bhardwaj N. Harnessing the immune system to treat cancer. J Clin Invest 2007, 117:1130-1136.